This trial is active not recruiting!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Asthma
Phase
-
This is an observational trial.
You are contributing to medical knowledge about your condition.
Show me locations

The purpose

This study is a special drug use investigation program of NUCALA (a brand name for Mepolizumab) administered subcutaneously (SC). In this study the information regarding the safety and effectiveness of long term use of NUCALA after subcutaneous injection will be collected from Asthma subjects in daily clinical practice. The observation period per subject will be 52 weeks from the initiation of NUCALA treatment with follow-up investigation for 2 years after the observation period. NUCALA is a registered trademark of the GlaxoSmithKline [GSK] group of companies

Provided treatments

  • Drug: NUCALA Injection
Tris trial is registered with FDA with number: NCT03028480. The sponsor of the trial is GlaxoSmithKline and it is looking for 1000 volunteers for the current phase.
Official trial title:
Nucala® Subcutaneous Injection Special Drug Use Investigation (Long-Term)